GlassScriptPhysician profile
Kurt A Mccammon
NPI 1598743692
$66,542.86
in general payments reported to CMS, 2019-2025
31 companies · $503 in 2025
The $503 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).
See the full distribution for Urogynecology and Reconstructive Pelvic Surgery (Urology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $28K · 2021: $68.55 · 2022: $414 · 2023: $265 · 2024: $214 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857 · Grant: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.63 |
| Grant | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $53,730.77 | 2019-2025 | Ams 700 |
| Allergan, INC. | $9,605.18 | 2019-2022 | |
| Janssen Biotech, INC. | $510.47 | 2019-2025 | Erleada |
| Axonics, INC. | $376.66 | 2022 | |
| Coloplast Corp | $220.32 | 2019 | |
| Astellas Pharma US INC | $204.72 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $196.86 | 2019-2025 | |
| Medtronic, INC. | $173.85 | 2021-2023 | Interstim |
| C. R. Bard, INC. & Subsidiaries | $152.81 | 2023-2025 | Bard Urinary Drainage Bag |
| Neotract INC. | $152.53 | 2019 | |
| Dendreon Pharmaceuticals LLC | $152.34 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $144.45 | 2019-2020 | |
| Innovation Technologies INC | $142.24 | 2025 | Irrisept |
| Pfizer INC. | $128.92 | 2019-2024 | |
| Abbvie INC. | $125.00 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calyxo, INC. | $120.33 | 2025 | Cvac Aspiration System |
| Karl Storz Endoscopy-America | $113.77 | 2023 | Flex-X |
| Olympus America INC. | $62.43 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $55.51 | 2019 | |
| Travere Therapeutics, INC. | $52.94 | 2019-2020 | |
| Blue Earth Diagnostics | $37.12 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $20.22 | 2019 | |
| Teleflex LLC | $19.51 | 2019 | |
| Medtronic USA, INC. | $18.90 | 2019 | |
| Telix Pharmaceuticals | $13.22 | 2023 | Illuccix |
| Tolmar Pharmaceuticals, INC. | $11.79 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$637,739.29 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Mccammon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.